Opus Point Partners Management’s Seres Therapeutics MCRB Stock Holding History

Opus Point Partners Management’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-700	Closed	-$158K	–	69
2017 Q1	$158K	Hold	700	–	–	0.12%	67
2016 Q4	$139K	Hold	700	–	–	0.11%	57
2016 Q3	$172K	Sell	700 -317	-31%	-$111K	0.1%	49
2016 Q2	$591K	Sell	1,017 -198	-16%	-$116K	0.57%	31
2016 Q1	$645K	Sell	1,215 -435	-26%	-$227K	0.5%	41
2015 Q4	$1.16M	Buy	+1,650	New	+$1.08M	0.77%	36

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Opus Point Partners Management's MCRB Position: Q2 2017 in Review

Opus Point Partners Management sold out of Seres Therapeutics (MCRB) in Q2 2017, closing a stake of 700 shares — an estimated $158K sold.

Opus Point Partners Management first reported a position in MCRB in Q4 2015 and held it in 6 quarters. The position peaked at $1.16M in Q4 2015. 74 funds tracked by Wall St. Rank hold MCRB as of Q2 2017.

Opus Point Partners Management reported no remaining Seres Therapeutics position as of Q2 2017 after selling out during the quarter.
Opus Point Partners Management sold 700 Seres Therapeutics shares in Q2 2017, an estimated $158K.
Opus Point Partners Management first reported a position in Seres Therapeutics in Q4 2015 and held it in 6 quarters.
Opus Point Partners Management's Seres Therapeutics position peaked at $1.16M in Q4 2015.
74 funds tracked by Wall St. Rank held Seres Therapeutics as of Q2 2017.

Based on Opus Point Partners Management's 13F filing for Q2 2017, filed 14 Aug 2017.